MAP2K7 and metastatic neoplasm: We then detail recent advances concerning the management of those tumors, especially focusing on parenchyma-sparing surgery in localized disease and pharmacological therapies targeting mTOR, MEK and HIF2-α in advanced/metastatic disease.